Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael C. Laufersweiler is active.

Publication


Featured researches published by Michael C. Laufersweiler.


Chemical Research in Toxicology | 2013

Framework for identifying chemicals with structural features associated with the potential to act as developmental or reproductive toxicants.

Shengde Wu; Joan Fisher; Jorge M. Naciff; Michael C. Laufersweiler; Cathy Lester; George P. Daston; Karen Blackburn

Developmental and reproductive toxicity (DART) end points are important hazard end points that need to be addressed in the risk assessment of chemicals to determine whether or not they are the critical effects in the overall risk assessment. These hazard end points are difficult to predict using current in silico tools because of the diversity of mechanisms of action that elicit DART effects and the potential for narrow windows of vulnerability. DART end points have been projected to consume the majority of animals used for compliance with REACH; thus, additional nonanimal predictive tools are urgently needed. This article presents an empirically based decision tree for determining whether or not a chemical has receptor-binding properties and structural features that are consistent with chemical structures known to have toxicity for DART end points. The decision tree is based on a detailed review of 716 chemicals (664 positive, 16 negative, and 36 with insufficient data) that have DART end-point data and are grouped into defined receptor binding and chemical domains. When tested against a group of chemicals not included in the training set, the decision tree is shown to identify a high percentage of chemicals with known DART effects. It is proposed that this decision tree could be used both as a component of a screening system to identify chemicals of potential concern and as a component of weight-of-evidence decisions based on structure-activity relationships (SAR) to fill data gaps without generating additional test data. In addition, the chemical groupings generated could be used as a starting point for the development of hypotheses for in vitro testing to elucidate mode of action and ultimately in the development of refined SAR principles for DART that incorporate mode of action (adverse outcome pathways).


Regulatory Toxicology and Pharmacology | 2018

Structure activity relationship (SAR) toxicological assessments: The role of expert judgment

Cathy Lester; Allison Reis; Michael C. Laufersweiler; Shengde Wu; Karen Blackburn

ABSTRACT Structure activity relationships (SAR) and read‐across are widely used animal alternative approaches for filling toxicological data gaps. A framework describing the use of expert judgment in evaluating analogs for SAR has been published and widely cited, however, reliance on expert judgment can introduce inconsistent results across experts and hinder transparency. Here we explore the use of a quantitative similarity score between an analog and a Structure of Interest (SOI) to see if these scores correlate with the expert judgement‐based suitability rankings. We find these global similarity scores representing a “whole‐molecule” view of similarity to be insensitive to differences in local structure which may be important for toxicity, and, therefore, cannot be substituted for expert judgement‐based similarity rankings. In this paper, we suggest that the next step in the progression of SAR approaches retains the insights from expert judgment, but facilitates consistency and transparency through the development of rating “rules”. This report outlines and defines analog rating rules for several compound categories. While not comprehensive, the exercises demonstrate the development of rules for categories with a large spread in molecular weight and alkyl chain length and explains the advantages that we see in this approach compared to relying solely on a computational approach or an unstructured expert judgement approach. These rules may be incorporated into analog searching work flows to define boundaries for analogs “suitable” for read‐across. HighlightsExpert judgment in analog selection for read‐across can introduce inconsistent results across experts and hinder transparency.Quantitative similarity scores do not correlate with expert judgement‐based similarity rankings.Rating “rules” can be developed to standardize expert‐judgment based analog rankings.


Regulatory Toxicology and Pharmacology | 2012

Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern.

Michael C. Laufersweiler; Bernard Gadagbui; Irene M. Baskerville‐Abraham; Andrew Maier; Alison Willis; Anthony R. Scialli; Gregory J. Carr; Susan P. Felter; Karen Blackburn; George P. Daston


Journal of Medicinal Chemistry | 2001

Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.

Stanislaw Pikul; Norman Eugene Ohler; Greg Ciszewski; Michael C. Laufersweiler; Neil Gregory Almstead; Biswanath De; Michael G. Natchus; Lily C. Hsieh; Michael J. Janusz; Sean X. Peng; Todd M. Branch; Selane L. King; and Yetunde O. Taiwo; Glen E. Mieling


Bioorganic & Medicinal Chemistry Letters | 2006

Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-γ binding agents with potential application to the treatment of osteoporosis

Corey R. Hopkins; Steven Victor O'Neil; Michael C. Laufersweiler; Yili Wang; Matthew Pokross; Marlene Mekel; Artem G. Evdokimov; Richard Walter; Maria Kontoyianni; Maria E. Petrey; Georgios Sabatakos; Jeff T. Roesgen; Eloise Richardson; Thomas Prosser Demuth


Bioorganic & Medicinal Chemistry | 2007

Synthesis and evaluation of unsaturated caprolactams as interleukin-1β converting enzyme (ICE) inhibitors

Yili Wang; Steven V. O’Neil; John August Wos; Kofi A. Oppong; Michael C. Laufersweiler; David Lindsey Soper; Christopher D. Ellis; Mark William Baize; Amy N. Fancher; Wei Lu; Maureen K. Suchanek; Richard L. Wang; William P. Schwecke; Charles A. Cruze; Maria Buchalova; Marina Belkin; Biswanath De; Thomas P. Demuth


Bioorganic & Medicinal Chemistry Letters | 2005

Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1β converting enzyme inhibitors

Steven V. O’Neil; Yili Wang; Michael C. Laufersweiler; Kofi A. Oppong; David Lindsey Soper; John August Wos; Christopher D. Ellis; Mark William Baize; Gregory Kent Bosch; Amy N. Fancher; Wei Lu; Maureen K. Suchanek; Richard L. Wang; Biswanath De; Thomas P. Demuth


Archive | 2003

Derivatives of azepine and thiazepan as interleukin converting enzyme inhibitors

John August Wos; Ylil Wang; Kofi A. Oppong; Steven Victor O'neill; Michael C. Laufersweiler; David Lindsey Soper; Biswanath De; Thomas Posser Demuth


Bioorganic & Medicinal Chemistry | 2006

Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1β converting enzyme (ICE) inhibitors

David Lindsey Soper; Justin Sheville; Steven V. O’Neil; Yili Wang; Michael C. Laufersweiler; Kofi A. Oppong; John August Wos; Christopher D. Ellis; Mark William Baize; Amy N. Fancher; Wei Lu; Maureen K. Suchanek; Richard L. Wang; William P. Schwecke; Charles A. Cruze; Maria Buchalova; Marina Belkin; Fred Christian Wireko; Amanda Ritter; Biswanath De; Difei Wang; Thomas P. Demuth


Bioorganic & Medicinal Chemistry Letters | 2005

Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1β synthesis

Kofi A. Oppong; Christopher D. Ellis; Michael C. Laufersweiler; Steven V. O’Neil; Yili Wang; David Lindsey Soper; Mark William Baize; John August Wos; Biswanath De; Gregory Kent Bosch; Amy N. Fancher; Wei Lu; Maureen K. Suchanek; Richard L. Wang; Thomas P. Demuth

Collaboration


Dive into the Michael C. Laufersweiler's collaboration.

Researchain Logo
Decentralizing Knowledge